Key regions: United Kingdom, Brazil, Europe, France, Canada
The Anti-Fibrinolytic Drugs market in G7 is witnessing a steady growth in recent years.
Customer preferences: Anti-Fibrinolytic Drugs are used to prevent blood clots and are prescribed for patients with bleeding disorders. The increasing prevalence of bleeding disorders and surgical procedures in the aging population is driving the demand for Anti-Fibrinolytic Drugs in G7 countries. Additionally, the rise in trauma cases and sports-related injuries is also contributing to the growth of the market.
Trends in the market: The Anti-Fibrinolytic Drugs market is witnessing a shift towards the development of new and advanced drugs. Manufacturers are investing heavily in research and development to introduce new drugs with better efficacy and fewer side effects. The market is also witnessing an increasing trend towards the use of combination therapy, where Anti-Fibrinolytic Drugs are used in combination with other drugs to improve treatment outcomes.
Local special circumstances: In the US, the Anti-Fibrinolytic Drugs market is witnessing a significant growth owing to the high prevalence of bleeding disorders and the increasing number of surgical procedures. In Japan, the market is witnessing a shift towards the use of new-generation Anti-Fibrinolytic Drugs owing to their better efficacy and safety profile. In Europe, the market is witnessing a steady growth owing to the increasing number of trauma cases and sports-related injuries.
Underlying macroeconomic factors: The increasing healthcare expenditure and the rise in disposable income in G7 countries are driving the growth of the Anti-Fibrinolytic Drugs market. Additionally, the favorable reimbursement policies and the increasing awareness among patients about the benefits of Anti-Fibrinolytic Drugs are also contributing to the growth of the market. However, the high cost of Anti-Fibrinolytic Drugs and the stringent regulatory framework are some of the factors that are hindering the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
